Document text
Principal Investigator: Chun Chieh Hsu
Organization: RUTGERS BIOMEDICAL AND HEALTH SCIENCES
Fiscal Year: 2024
Award: $108,000
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ABSTRACT
The COVID-19 pandemic has had a devastating worldwide impact on health and economy. There is still
no effective treatment, and the full extent of COVID-19 pathogenesis remains unclear. In particular,
mechanisms for SARS-CoV-2 evasion of host immune surveillance remain poorly understood. I am interested
in exploring both SARS-CoV-2 viral factors that block cellular translation and their roles in viral immune
evasion. I have discovered that SARS-CoV-2 nonstructural protein 14 (NSP14) inhibits host translation and
subsequently suppresses the innate immune response. Furthermore, my data suggest that the guanine-N7-
methytransferase (N7-MTase) activity of NSP14 is required to inhibit translation, which catalyzes N7-
methylguanosine (m7G) modification at 5’ cap guanosine. However, how m7G modification restricts cellular
translation is unclear. Moreover, our data also showed that NSP14 inhibits the expression of MHC-I molecules
on the cell surface and this also depends on its N7-MTase activity. However, whether NSP14 dampens MHC-I
antigen presentation and cytotoxic CD8+ T cell responses requires further study. I hypothesize that NSP14
induces RNA m7G modification in SARS-CoV-2 infection and that shuts down cellular translation. I further
hypothesize that such activity restricts the MHC-I antigen presentation pathway to escape T cell responses.
The central objectives in this proposal are to define the molecular mechanism by which SARS-CoV-2 NSP14
inhibits cellular translation and enhance our understanding of how SARS-CoV-2 escapes T cell-mediated
immunity. In Aim 1, I will determine the role of RNA m7G modification in translation inhibition in SARS-CoV-2
infection. In Aim 2, I will define how NSP14 restricts MHC-I antigen presentation and T cell responses. These
two aims will address how SARS-CoV-2 infection can affect T cell-mediated immunity. I expect that our
findings will uncover new strategies to develop new antiviral therapeutics for COVID-19 and help gain new
insights into understanding the biology of COVID-19 pathogenesis.
My career goal is to become an independent investigator studying virus-host interaction of infectious
diseases, with a special focus on translational regulation and viral immune evasion. The proposed K22 grant
will provide me with advanced training and skills to build specific expertise necessary to execute the proposed
project and become independent in this field, including expertise in: 1. Immunology and Virology, 2. post-
transcriptional modification and translational regulation research, and 3. skills necessary to head an
independent research laboratory. To achieve these goals, I have assembled a Professional/Scientific Advisory
Committee consisting of experts in SARS-CoV-2 Virology, Immunobiology, RNA Biology, and Bioinformatics.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Advisory Committees><Affect><Anti-viral Agents><Anti-viral Response><Antigen Presentation><Antigen Presentation Pathway><Antigen Processing and Presentation><Bio-Informatics><Bioinformatics><Biology><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 pathogenesis><COVID-19 period><COVID-19 public health crisis><COVID-19 therapeutics><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 pathogenesis><COVID19 virus><CV-19><Causality><Cell Mediated Immunology><Cell surface><Cell-Mediated Immunity><Cellular Immunity><Cessation of life><Class I Antigens><Class I Major Histocompatibility Antigens><CoV-2><CoV2><Communicable Diseases><Complex Class 1><Coronavirus Infectious Disease 2019><Data><Death><Detection><Development><EC 2.1.1><Enzyme Gene><Enzymes><Etiology><Genes><Goals><Grant><Guanine><Guanosine><Head><Health><Histocompatibility Antigens Class I><Histocompatibility Complex><Histocompatibility Complices><IFN><IFN antagonist><Immune Evasion><Immune Surveillance><Immune response><Immunobiology><Immunologic Surveillance><Immunologic Surveillances><Immunological Surveillance><Immunological Surveillances><Immunological response><Immunology><Immunophysiology><Immunosurveillance><In Vitro><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Innate Immune Response><Interferon Type I><Interferons><Investigators><Knowledge><Laboratory Research><MHC Class I Molecule><MHC Class I Protein><MHC class I antigen><Major Histocompatibility Complex><Major Histocompatibility Complex Class 1><Major Histocompatibility Complices><Manuscripts><Mediating><Messenger RNA><Methylation><Methyltransferase><Modification><Molecular><Non-Polyadenylated RNA><Non-structural Protein><Nonstructural Protein><Play><Position><Positioning Attribute><Protein Biosynthesis><Proteins><Publications><Publishing><RNA><RNA Gene Products><Research><Research Personnel><Researchers><Ribonucleic Acid><Ribosomal Peptide Biosynthesis><Ribosomal Protein Biosynthesis><Ribosomal Protein Synthesis><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 pathogenesis><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Surface><System><T cell response><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Task Forces><Training><Translational Inhibition><Translational Regulation><Translational Repression><Translations><Viral><Viral Diseases><Virus><Virus Diseases><Wuhan coronavirus><advisory team><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral immunity><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy development><anti-virals><antiviral development><antiviral drug development><antiviral immunity><antiviral therapeutic development><antiviral therapy development><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><blocking factor><career><causation><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 pathogenesis><coronavirus disease-19 virus><coronavirus infectious disease-19><cytotoxic CD8 T cells><cytotoxic CD8 T lymphocyte><design><designing><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><disease causation><effective therapy><effective treatment><global health><hCoV19><host response><immune evasive><immune system response><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><insight><interest><interferon antagonist><mRNA><mRNA Stability><mRNA Translation><methylase><nCoV2><new vaccines><next generation vaccines><novel vaccines><pathogenic virus><posttranscriptional><prevent><preventing><protein synthesis><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 pathogenesis><skills><social role><therapeutic target><therapeutics against COVID-19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><thymus derived lymphocyte><translation><transmethylase><viral infection><viral pathogen><virology><virus host interaction><virus infection><virus pathogen><virus-induced disease>